(Q35008766)

5 August 2017

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

13

Henry S Friedman

1 reference

5 August 2017

4

Sridharan Gururangan

1 reference

5 August 2017

2

Annick Desjardins

1 reference

5 August 2017

11

Allan H Friedman

1 reference

5 August 2017

1

David A Reardon

1 reference

5 August 2017

7

Roger McLendon

1 reference

5 August 2017

6

Jeremy N Rich

1 reference

5 August 2017

12

James J Vredenburgh

1 reference

5 August 2017

3

Katherine Peters

1 reference

5 August 2017

8

James E Herndon

1 reference

5 August 2017

9

Jennifer Marcello

1 reference

5 August 2017

10

Stevie Threatt

1 reference

5 August 2017

John Sampson

5

1 reference

5 August 2017

19 September 2010

1 reference

Journal of Neuro-Oncology

5 August 2017

1 reference

5 August 2017

103

1 reference

5 August 2017

2

1 reference

5 August 2017

371-379

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-010-0403-6

5 August 2017

0 references

cites work

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

The anti-angiogenic basis of metronomic chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Inhibition of angiogenesis by non-toxic doses of temozolomide

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Recurrent chiasmatic-hypothalamic glioma treated with oral etoposide

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Interim analyses for randomized clinical trials: the group sequential approach

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0403-6

A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3102515

The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin

26 October 2018

1 reference

12 December 2020

A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients

1 reference

12 December 2020

Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study

1 reference

12 December 2020

Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth

1 reference

12 December 2020

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

12 December 2020

10.1007/S11060-010-0403-6

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

PubMed ID

20853132